• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

噻吩并嘧啶酮和硫脲类化合物的混合物作为抗结核药物的研究:SAR 和对接研究。

Hybrids of thienopyrimidinones and thiouracils as anti-tubercular agents: SAR and docking studies.

机构信息

Division of Organic Chemistry, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pune 411 008, India.

Combichem Bio-resource Centre, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pune 411 008, India.

出版信息

Eur J Med Chem. 2017 Feb 15;127:459-469. doi: 10.1016/j.ejmech.2017.01.009. Epub 2017 Jan 9.

DOI:10.1016/j.ejmech.2017.01.009
PMID:28103537
Abstract

A number of hybrid molecules containing thienopyrimidinones and thiouracil moieties were designed, synthesized and tested against Mycobacterium tuberculosis H37Ra wherein it was observed that the compounds 11-14 exhibited antitubercular activity in vitro (MIC 7.6-19.1 μg/mL, 12-35 μM) against dormant stage while the compound 15 exhibited antitubercular activity in vitro against dormant (MIC 23.4 μg/mL, 41 μM) as well as active (MIC 25.4 μg/mL, 45 μM) stage. Structural modifications of the compound 15 were carried out to study the structure-activity relationship and it was observed that the compound 18 exhibited antitubercular activity comparable to the compound 15. Cytotoxicity studies revealed that these molecules were non-toxic. The docking study of the compound 15 showed that there was binding with the active site of mycobacterial pantothenate synthetase. Further docking studies led to the synthesis of the compounds 16 and 17 and the antitubercular activity screening results showed that these compounds have significant antitubercular activity. The compounds 15-18 (MIC 11-29 μg/mL, 19-51 μM) can be used as starting points for further optimization. The synthetic strategies used in the present work have potential to prepare a large number of compounds for further refinement of structures and the present results will be very useful in the development of a new class of antimycobacterial agents.

摘要

设计、合成并测试了一系列含有噻吩并嘧啶酮和硫尿嘧啶部分的杂化分子,观察到化合物 11-14 在体外对休眠期分枝杆菌 H37Ra 具有抗结核活性(MIC 7.6-19.1μg/mL,12-35μM),而化合物 15 在体外对休眠期(MIC 23.4μg/mL,41μM)和活性期(MIC 25.4μg/mL,45μM)均具有抗结核活性。对化合物 15 进行了结构修饰,以研究构效关系,观察到化合物 18 具有与化合物 15 相当的抗结核活性。细胞毒性研究表明这些分子没有毒性。化合物 15 的对接研究表明,它与分枝杆菌泛酸合酶的活性位点结合。进一步的对接研究导致了化合物 16 和 17 的合成,抗结核活性筛选结果表明这些化合物具有显著的抗结核活性。化合物 15-18(MIC 11-29μg/mL,19-51μM)可作为进一步优化的起点。本工作中使用的合成策略有潜力制备大量化合物,以进一步改进结构,目前的结果将非常有助于开发新类抗分枝杆菌药物。

相似文献

1
Hybrids of thienopyrimidinones and thiouracils as anti-tubercular agents: SAR and docking studies.噻吩并嘧啶酮和硫脲类化合物的混合物作为抗结核药物的研究:SAR 和对接研究。
Eur J Med Chem. 2017 Feb 15;127:459-469. doi: 10.1016/j.ejmech.2017.01.009. Epub 2017 Jan 9.
2
Synthesis, biological evaluation and molecular docking study of some novel indole and pyridine based 1,3,4-oxadiazole derivatives as potential antitubercular agents.一些新型吲哚和吡啶基1,3,4-恶二唑衍生物作为潜在抗结核药物的合成、生物学评价及分子对接研究
Bioorg Med Chem Lett. 2016 Apr 1;26(7):1776-83. doi: 10.1016/j.bmcl.2016.02.043. Epub 2016 Feb 16.
3
Design, Synthesis, and in vitro antitubercular activity of 1,2,3-triazolyl-dihydroquinoline derivatives.设计、合成及 1,2,3-三唑基二氢喹啉衍生物的体外抗结核活性。
Chem Biol Drug Des. 2018 Jul;92(1):1315-1323. doi: 10.1111/cbdd.13196. Epub 2018 May 18.
4
Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors.2-甲基咪唑并[1,2-a]吡啶-3-甲酰胺作为结核分枝杆菌泛酸合成酶抑制剂的鉴定与开发
Bioorg Med Chem. 2014 Aug 1;22(15):4223-32. doi: 10.1016/j.bmc.2014.05.038. Epub 2014 May 23.
5
Quinolidene based monocarbonyl curcumin analogues as promising antimycobacterial agents: Synthesis and molecular docking study.基于喹诺里定的单羰基姜黄素类似物作为有前景的抗分枝杆菌剂:合成与分子对接研究
Bioorg Med Chem Lett. 2017 Feb 15;27(4):922-928. doi: 10.1016/j.bmcl.2017.01.004. Epub 2017 Jan 5.
6
Design, synthesis, and pharmacological evaluation of fluorinated azoles as anti-tubercular agents.氟唑类化合物的设计、合成与抗结核活性评价。
Arch Pharm (Weinheim). 2018 Feb;351(2). doi: 10.1002/ardp.201700294. Epub 2018 Jan 2.
7
Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.新型吡唑啉类抗结核和细胞毒性药物的合成、生物学评价及分子对接研究
Infect Disord Drug Targets. 2019;19(3):310-321. doi: 10.2174/1871526519666181217120626.
8
Novel Benzylidenehydrazide-1,2,3-Triazole Conjugates as Antitubercular Agents: Synthesis and Molecular Docking.新型苄叉腙-1,2,3-三唑类化合物的抗结核活性:合成与分子对接。
Mini Rev Med Chem. 2019;19(14):1178-1194. doi: 10.2174/1389557518666180718124858.
9
Structure-guided design of thiazolidine derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors.作为结核分枝杆菌泛酸合成酶抑制剂的噻唑烷衍生物的结构导向设计
ChemMedChem. 2014 Nov;9(11):2538-47. doi: 10.1002/cmdc.201402171. Epub 2014 Aug 22.
10
Design of new phenothiazine-thiadiazole hybrids via molecular hybridization approach for the development of potent antitubercular agents.通过分子杂交方法设计新型吩噻嗪-噻二唑杂化物以开发高效抗结核药物。
Eur J Med Chem. 2015 Dec 1;106:75-84. doi: 10.1016/j.ejmech.2015.10.035. Epub 2015 Oct 23.

引用本文的文献

1
Unravelling the potency of the 4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonitrile scaffold with -arylamide hybrids as PIM-1 kinase inhibitors: synthesis, biological activity and studies.探索以-芳基酰胺杂化物作为PIM-1激酶抑制剂的4-氧代-2-硫代-1,2,3,4-四氢嘧啶-5-甲腈支架的效力:合成、生物活性及研究
RSC Med Chem. 2025 Mar 28. doi: 10.1039/d5md00021a.
2
Dihydroxyphenyl- and Heteroaromatic-Based Thienopyrimidinones to Tackle HIV-1 LEDGF/p75-Dependent IN Activity.基于二羟基苯基和杂芳基的噻吩并嘧啶酮用于应对HIV-1 LEDGF/p75依赖性整合酶活性。
Molecules. 2023 Sep 19;28(18):6700. doi: 10.3390/molecules28186700.
3
Discovery of pyrimidine-tethered benzothiazole derivatives as novel anti-tubercular agents towards multi- and extensively drug resistant .
发现嘧啶键合苯并噻唑衍生物作为新型抗结核药物,针对多药和广泛耐药性。
J Enzyme Inhib Med Chem. 2023 Dec;38(1):2250575. doi: 10.1080/14756366.2023.2250575.